Individual Bioequivalence Interim Approach Proposed To Gather More Data
Executive Summary
An expert panel assembled by FDA is proposing that the agency adopt an interim approach to new bioequivalence methods, panel member Leslie Benet, PhD, University of California(San Francisco, told an American Association of Pharmaceutical Scientists workshop held March 16-18 in Arlington, Va.